Appears on
Articles20
T
Part I: EchoNext Clears FDA for Six Structural Heart Conditions Off a Standard ECG, Lands on OpenEvidence, and Logs the First AI-Triggered Heart Transplant: Reading the Cardiac Screening Land Grab
0
Thoughts on Healthcare Markets & Technology8d agoT
Part II: EchoNext Clears FDA for Six Structural Heart Conditions Off a Standard ECG, Lands on OpenEvidence, and Logs the First AI-Triggered Heart Transplant: Reading the Cardiac Screening Land Grab
0
Thoughts on Healthcare Markets & Technology8d agoT
EchoNext Clears FDA for Six Structural Heart Conditions Off a Standard ECG, Lands on OpenEvidence, and Logs the First AI-Triggered Heart Transplant: Reading the Cardiac Screening Land Grab
0
Thoughts on Healthcare Markets & Technology8d agoT
The Audit Economy Shows Up Early: A Five Point Six Million Dollar HHS Contract, an AI That Flags TEFCA Participants, and What the January Epic vs Health Gorilla Forecast Got Right and Wrong
0
Thoughts on Healthcare Markets & Technology7d agoT
The Audit Economy Shows Up Early: A Five Point Six Million Dollar HHS Contract, an AI That Flags TEFCA Participants, and What the January Epic v Health Gorilla Forecast Got Right and Wrong
0
Thoughts on Healthcare Markets & Technology7d agoT
Part I: FDA Drops the Hammer on the Gray Market Peptide Craze: A Deep Dive into the July 2026 Pharmacy Compounding Advisory Committee Meeting
0
Thoughts on Healthcare Markets & Technology6d agoT
Part II: FDA Drops the Hammer on the Gray Market Peptide Craze: A Deep Dive into the July 2026 Pharmacy Compounding Advisory Committee Meeting
0
Thoughts on Healthcare Markets & Technology6d agoT
FDA Drops the Hammer on the Gray Market Peptide Craze: A Deep Dive into the July 2026 Pharmacy Compounding Advisory Committee Meeting
0
Thoughts on Healthcare Markets & Technology6d agoT
Anthropic Ships an AI Workbench for Wet Lab and Computational Scientists: A Deep Look at How Claude Science Fuses Compute, 60 Plus Databases, and Reviewer Agents into One Environment
0
Thoughts on Healthcare Markets & Technology4d agoT
Anthropic Ships an AI Workbench for Wet Lab and Computational Scientists: A Deep Look at How Claude Science Fuses Compute, 60 Plus Databases, and Reviewer Agents into One Environment
0
Thoughts on Healthcare Markets & Technology4d agoT
Part I: 25x the Surgeon’s Pay: How Surgical Assistants Are Using No Surprises Act Arbitration Loopholes to Out Earn the Doctors They Assist in Operating Rooms Nationwide
0
Thoughts on Healthcare Markets & Technology4d agoT
Part II: 25x the Surgeon’s Pay: How Surgical Assistants Are Using No Surprises Act Arbitration Loopholes to Out Earn the Doctors They Assist in Operating Rooms Nationwide
0
Thoughts on Healthcare Markets & Technology4d agoT
Twenty Five Times the Surgeon’s Pay: How Surgical Assistants Are Using No Surprises Act Arbitration Loopholes to Out Earn the Doctors They Assist in Operating Rooms Nationwide
0
Thoughts on Healthcare Markets & Technology4d agoT
The Site-of-Care Migration Engine: The Company to Build on the CY2027 OPPS and ASC Rule’s IPO Phase-Out, Site-Neutral Imaging, 340B ASP-Minus-33.4-Percent Haircut, and Price Transparency RFI
0
Thoughts on Healthcare Markets & Technology3d agoT
The Site-of-Care Migration Engine: The Company to Build on the CY2027 OPPS and ASC Rule’s IPO Phase-Out, Site-Neutral Imaging, 340B ASP-Minus-33.4-Percent Haircut, and Price Transparency RFI
0
Thoughts on Healthcare Markets & Technology2d agoT
Part I: When the Toolmaker Decides to Also Make the Drugs: Anthropic’s Claude Science Launch, Its In-House Preclinical Bet on Neglected Diseases & What Tool Vs. Competitor Tension Means for Pharma AI
0
Thoughts on Healthcare Markets & Technology2d agoT
Part II: When the Toolmaker Decides to Also Make the Drugs: Anthropic’s Claude Science Launch, Its In-House Preclinical Bet on Neglected Diseases & What Tool Vs. Competitor Tension Means for Pharma AI
0
Thoughts on Healthcare Markets & Technology2d agoT
When the Toolmaker Decides to Also Make the Drugs: Anthropic’s Claude Science Launch, Its In-House Preclinical Bet on Neglected Diseases & What Tool Vs. Competitor Tension Means for Pharma AI
0
Thoughts on Healthcare Markets & Technology2d agoT
CMS-1844-P, Home Health Fraud, and the Founder Opportunity: How Retroactive Revocations and Geographic Saturation Rules Turn Medicare Program Integrity Into a Buildable Market
0
Thoughts on Healthcare Markets & Technology1d agoT
CMS-1844-P, Home Health Fraud, and the Founder Opportunity: How Retroactive Revocations and Geographic Saturation Rules Turn Medicare Program Integrity Into a Buildable Market
0
Thoughts on Healthcare Markets & Technology1d ago